← 返回

多肽刺激的 PBMC 可产生 T(EM)/T(CM),用于多发性骨髓瘤的过继性细胞治疗

英文原题:Multipeptide stimulated PBMCs generate T(EM)/T(CM) for adoptive cell therapy in multiple myeloma.

查看英文原题

Multipeptide stimulated PBMCs generate T(EM)/T(CM) for adoptive cell therapy in multiple myeloma.

PubMed 2021/09/28(内容时间) Oncotarget

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

多发性骨髓瘤(MM)患者因治疗耐药的发生而出现疾病复发。越来越多的证据表明,免疫治疗策略可以提供持久的缓解。在此,我们评估了过继性细胞转移(ACT)的可能性,通过采用我们先前设计的方案,从MM患者外周血单核细胞(PBMCs)中分离并生成离体T细胞。

我们设计了来自抗原(Ags)的肽段,包括在MM中过表达的癌睾丸抗原(CTAs)。我们将来自不同健康供者(HDs)的PBMCs暴露于单一肽段。

我们观察到,将PBMCs暴露于不同的单一肽段序列后,可重复地产生抗原特异性分化簇4+(CD4+)和CD8+ T细胞应答。这些肽段序列被用于编制四种不同的肽段混合物。来自MM患者或HDs PBMCs的初始T细胞识别了所有四种肽段混合物中的同源Ag,从而生成多克隆抗原特异性CD4+和CD8+效应和中枢记忆T(分别为T EM和T CM)细胞,这些细胞在二次再刺激时产生干扰素-γ(IFN-γ)、颗粒酶B和穿孔素。

此外,本研究表明,MM患者的免疫细胞能够转换代谢程序以诱导效应和记忆应答。已鉴定出多种肽段和混合物可诱导IFN-γ+、T1型、代谢活跃的T细胞,从而为在I期临床试验中进行ACT的可行性测试铺平了道路。

展开英文摘要原文

Multiple Myeloma (MM) patients suffer disease relapse due to the development of therapeutic resistance. Increasing evidence suggests that immunotherapeutic strategies can provide durable responses.

Here we evaluate the possibility of adoptive cell transfer (ACT) by generating ex vivo T cells from peripheral blood mononuclear cells (PBMCs) isolated from MM patients by employing our previously devised protocols.

We designed peptides from antigens (Ags) including cancer testis antigens (CTAs) that are over expressed in MM.

We exposed PBMCs from different healthy donors (HDs) to single peptides.

We observed reproducible Ag-specific cluster of differentiation 4 + (CD4 + ) and CD8 + T cell responses on exposure of PBMCs to different single peptide sequences. These peptide sequences were used to compile four different peptide cocktails.

Naïve T cells from PBMCs from MM patients or HDs recognized the cognate Ag in all four peptide cocktails, leading to generation of multiclonal Ag-specific CD4 + and CD8 + effector and central memory T (T EM and T CM , respectively) cells which produced interferon-gamma (IFN-γ), granzyme B and perforin on secondary restimulation.

Furthermore, this study demonstrated that immune cells from MM patients are capable of switching metabolic programs to induce effector and memory responses. Multiple peptides and cocktails were identified that induce IFN-γ + , T1-type, metabolically active T cells, thereby paving the way for feasibility testing of ACT in phase I clinical trials.

论文信息

作者
Vardam-Kaur T、Pathangey LB、McCormick DJ、Bergsagel PL、Cohen PA、Gendler SJ
单位
Department of Immunology, Mayo Clinic, Scottsdale, AZ, USA.United States
期刊
Oncotarget2021 Sep 28
原文标识
PubMed 34611479 · DOI 10.18632/oncotarget.28067